On October 6, 2025, Biogen Inc. and Eisai Co. announced that the lecanemab‑irmb subcutaneous injection, marketed in the United States as LEQEMBI IQLIK™, is now available for patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The new formulation provides a weekly 360 mg autoinjector that can be administered at home after patients complete an 18‑month course of intravenous (IV) infusions at 10 mg/kg every two weeks.
The subcutaneous maintenance regimen allows patients to either continue IV infusions every four weeks or switch to the weekly at‑home injection, offering greater convenience and reducing the need for infusion‑center visits. LEQEMBI IQLIK is the first anti‑amyloid therapy to provide an at‑home delivery option following initial IV treatment, potentially improving adherence and expanding access to the drug’s disease‑modifying benefits.
Biogen and Eisai have also launched the LEQEMBI Companion™ program, which includes nurse educators, an injection‑tracking app, and a patient assistance program that offers the drug at no cost to eligible uninsured or underinsured patients. The companion resources aim to support patients throughout the treatment journey, from initiation through maintenance therapy, and to address logistical and financial barriers to care.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.